MRSA - The Staph Superbug
-
Mechanism: The mecA gene encodes Penicillin-Binding Protein 2a (PBP2a). This altered protein has a low affinity for β-lactam antibiotics, conferring resistance by preventing their binding.
-
Clinical Syndromes:
- Community-Associated (CA-MRSA): Presents as skin/soft tissue infections (abscesses, boils). Virulence is often driven by Panton-Valentine Leukocidin (PVL) toxin.
- Hospital-Associated (HA-MRSA): Causes more invasive disease (bacteremia, pneumonia, endocarditis) in patients with recent healthcare exposure.
-
Diagnosis:
- Rapid: NAAT for the mecA gene offers fast identification.
- Culture: Chromogenic agar for screening; Kirby-Bauer testing with a cefoxitin disk confirms resistance.
⭐ The PVL toxin in CA-MRSA is linked to severe, necrotizing pneumonia, classically seen in healthy patients following an influenza infection.
VRE - Vexing Vancomycin Villain

- Mechanism: Acquired vanA or vanB genes alter the peptidoglycan precursor target.
- Terminal $D-Ala-D-Ala$ is changed to $D-Ala-D-Lac$.
- This substitution prevents vancomycin from binding effectively.
- Predominant Species:
- Enterococcus faecium is more frequently vancomycin-resistant than E. faecalis.
- Key Risk Factors:
- Prolonged hospitalization or ICU stay.
- Long-term antibiotic therapy, especially with vancomycin.
- Clinical Syndromes:
- Nosocomial infections, including UTIs, bacteremia, and endocarditis.
⭐ VRE can transfer its resistance genes to other bacteria, such as S. aureus, leading to the emergence of Vancomycin-Resistant Staphylococcus aureus (VRSA).
Treatment - The Resistance Rumble
| Drug | Mechanism & Key Side Effect | MRSA | VRE |
|---|---|---|---|
| Vancomycin | Inhibits cell wall synthesis by binding D-Ala-D-Ala. → Red Man Syndrome, nephrotoxicity. | ✅ | ❌ |
| Daptomycin | Lipopeptide; depolarizes cell membrane. → Myopathy (monitor CPK). | ✅ | ✅ |
| Linezolid | Binds 50S subunit. → Thrombocytopenia, Serotonin Syndrome (risk with SSRIs). | ✅ | ✅ |
| Ceftaroline | 5th-gen cephalosporin; binds PBP2a. → Hemolytic anemia. | ✅ | ❌ |
| Tigecycline | Binds 30S subunit. → Severe nausea/vomiting; ↑ mortality warning. | ❌ | ✅ |
- MRSA resistance stems from the mecA gene, encoding an altered penicillin-binding protein (PBP2a), making it impervious to most beta-lactams.
- VRE resistance arises from the conversion of the peptidoglycan precursor from D-Ala-D-Ala to D-Ala-D-Lac.
- Key MRSA treatments include Vancomycin, Linezolid, and Daptomycin.
- For VRE, preferred agents are Linezolid and Daptomycin.
- Both are significant causes of nosocomial infections, particularly in immunocompromised patients.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app